Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: miglustat

« Back to Dashboard

Miglustat is the generic ingredient in one branded drug marketed by Actelion Pharms Ltd and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for miglustat. One supplier is listed for this compound.

Summary for Generic Name: miglustat

Tradenames:1
Patents:0
Applicants:1
NDAs:1
Drug Master File Entries: see list1
Suppliers: see list1
Therapeutic Class:Enzyme Replacements/Modifiers

Pharmacology for Ingredient: miglustat

Clinical Trials for: miglustat

A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
Status: Recruiting Condition: Pompe Disease; Hypersensitivity Reaction

Miglustat in Niemann-Pick Type C Disease
Status: Completed Condition: Niemann-Pick Type C Disease

Application of Miglustat in Patients With Niemann-Pick Type C
Status: Completed Condition: Niemann-Pick Disease Type C

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
Status: Terminated Condition: Cystic Fibrosis

Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease
Status: Completed Condition: Type 1 Gaucher Disease

Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis
Status: Active, not recruiting Condition: Gangliosidoses GM2

Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?
Status: Completed Condition: Cystic Fibrosis

Miglustat in Cystic Fibrosis
Status: Completed Condition: Cystic Fibrosis

Synergistic Enteral Regimen for Treatment of the Gangliosidoses
Status: Recruiting Condition: GM1 Gangliosidoses; GM2 Gangliosidoses; Tay-Sachs Disease; Sandhoff Disease

Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®
Status: Active, not recruiting Condition: Diarrhea

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd
ZAVESCA
miglustat
CAPSULE;ORAL021348Jul 31, 2003RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc